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A B S T R A C T
Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid that attracted a great attention for its ther-
apeutic potential against diﬀerent pathologies including skin diseases. However, although the eﬃcacy in pre-
clinical models and the clinical beneﬁts of CBD in humans have been extensively demonstrated, the molecular
mechanism(s) and targets responsible for these eﬀects are as yet unknown. Herein we characterized at the
molecular level the eﬀects of CBD on primary human keratinocytes using a combination of RNA sequencing
(RNA-Seq) and sequential window acquisition of all theoretical mass spectrometry (SWATH-MS). Functional
analysis revealed that CBD regulated pathways involved in keratinocyte diﬀerentiation, skin development and
epidermal cell diﬀerentiation among other processes. In addition, CBD induced the expression of several NRF2
target genes, with heme oxygenase 1 (HMOX1) being the gene and the protein most upregulated by CBD.
CRISPR/Cas9-mediated genome editing, RNA interference and biochemical studies demonstrated that the in-
duction of HMOX1 mediated by CBD, involved nuclear export and proteasomal degradation of the transcrip-
tional repressor BACH1. Notably, we showed that the eﬀect of BACH1 on HMOX1 expression in keratinocytes is
independent of NRF2. In vivo studies showed that topical CBD increased the levels of HMOX1 and of the pro-
liferation and wound-repair associated keratins 16 and 17 in the skin of mice. Altogether, our study identiﬁes
BACH1 as a molecular target for CBD in keratinocytes and sets the basis for the use of topical CBD for the
treatment of diﬀerent skin diseases including atopic dermatitis and keratin disorders.
1. Introduction
The skin serves as a protective barrier against the environment and
is constantly exposed to insults which can lead to the generation of
reactive oxygen species (ROS). While low levels of ROS act as in-
tracellular signalling messengers [1], high ROS levels lead to oxidative
stress, which is deleterious, as it damages cellular macromolecules [2].
Oxidative stress-induced cell damage can lead to chronic inﬂammation
and is involved in the pathogenesis of skin diseases, skin disorder and
skin aging [3]. To counteract the harmful accumulation of ROS, healthy
skin presents a battery of defence mechanisms including antioxidant
and detoxiﬁcation systems. Many of these systems are under the control
of nuclear factor erythroid 2-like 2 (NRF2), the master regulator of the
antioxidant responses. Under basal conditions, NRF2 is kept at low le-
vels by the negative regulator KEAP1 [4,5], a substrate adaptor protein
for the Cullin3-containing E3-ligase complex, that mediates NRF2 ubi-
quitination and subsequent degradation. Cell exposure to ROS or elec-
trophiles impairs the NRF2-KEAP1 binding, leading to NRF2 stabilisa-
tion [6]. NRF2 then can translocate to the nucleus where it binds to
antioxidant response elements (AREs) in the promoters of NRF2 target
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genes and activate their expression [7].
Among NRF2 target genes is the stress inducible enzyme HMOX1.
This enzyme catalyses the rate-limiting reaction in heme catabolism
and has important antioxidant and anti-inﬂammatory properties [8,9].
Due to these cytoprotective properties, HMOX1 is highly induced by a
variety of cellular stresses [10] (e.g. oxidative stress, UV irradiation,
hydrogen peroxide, nitric oxide, heavy metals, phorbol esters, lipopo-
lysaccharide and organic chemicals) and thus it is one of the more
widely used markers for stress responses. Although HMOX1 is positively
regulated by NRF2, its expression is also negatively regulated by the
transcription factor BTB And CNC Homology 1 (BACH1) [11,12]. Im-
portantly, the primary event leading to HMOX1 induction is the deac-
tivation of BACH1 repression [13]. The current model postulates that
BACH1 and NRF2 act together to control HMOX1 expression with the
negative eﬀect of BACH1 being dominant over the positive eﬀect of
NRF2; thus, BACH1 must be displaced for NRF2 to access the HMOX1
promoter and to induce its expression. Although HMOX1 is the main
and the best characterized BACH1 target gene, a subset of NRF2 target
genes have also been suggested to be BACH1 target genes (i.e. GCLC
and SQSTM1) [14,15]. In normal skin HMOX1 is expressed in the upper
epidermis, with the most prominent HMOX1 expression in the granular
layer [16]. Furthermore, HMOX1 expression is associated with kerati-
nocytes diﬀerentiation, and it is expressed in diﬀerentiated keratino-
cytes [16].
Cannabidiol (CBD) is the best studied non-psychotropic phyto-
cannabinoid and shows pleiotropic activities including antioxidant and
anti-inﬂammatory eﬀects [17–20]. Based on these properties, CBD
might have therapeutic utility in a number of conditions including skin
disorders. Additionally, it has been suggested that cannabinoids can be
an attractive therapeutic approach for the treatment of keratin disorder
such as epidermolysis bullosa (EB), a rare genodermatoses caused by
function-impairing mutations in keratins [21]. Interestingly a recent
observational study using self-initiated topical CBD use in 3 patients
with EB reported faster wound healing, less blistering, and amelioration
of pain in all patients [22].
Previous reports have shown that in cell types other than skin cells,
CBD induced the expression of HMOX1 and other NRF2-dependent
genes [23,24], however, the mechanism of action behind the eﬀect of
CBD on the NRF2 pathway is not known. In addition, to date no sys-
tematic analysis of the pathways regulated by CBD in keratinocytes has
been performed. Herein we show for the ﬁrst time that CBD is a BACH1
inhibitor and a weak NRF2 activator. Furthermore, we reveal that in
keratinocytes, HMOX1 expression is regulated by BACH1 in a NRF2-
independent manner. Finally, we show that topical CBD application in
mice increased the levels of HMOX1 in the epidermis (in agreement
with our results in cells) and induced the expression of wound-repair
and proliferation associated keratins 16 and 17.
2. Experimental procedures
2.1. Cell cultures
Normal human epidermal keratinocytes (NHEK) and Keratinocyte
growth medium were purchased to Innoprot SL (Biscaia, Spain). The
cells were cultured until conﬂuence in 60 cm2 plates with medium
change every 24–48 h. Then, the cells were cultured in fresh medium in
the presence or the absence of CBD (10 μM) for 24 h. HaCaT cells used
in the study have been validated by STR proﬁling and were routinely
tested for mycoplasma. The generation of HaCaT-ARE-Luc cells has
been described previously [25]. CRISPR-edited NRF2-KO HaCaT cells
were produced by transfecting HaCaT cells with pLentiCRISPR-v2 (a
gift from Dr Feng Zhang, Addgene plasmid #52961) containing a guide
RNA directed against the exon 2 of the NFE2L2 locus (which encodes
NRF2) (5′-TGGAGGCAAGATATAGATCT-3′). After 2 days of puromycin
selection, cells were clonally selected by serial dilution, and positive
clones were identiﬁed as previously described [26]. Control cells,
referred as HaCaT wild type (HaCaT WT), are the pooled population of
surviving cells transfected with an empty pLentiCRISPRv2 vector
treated with puromycin. All cell lines were grown in RPMI containing
10% FBS at 37 °C and 5% CO2.
2.2. Antibodies and reagents
Antibodies recognizing BACH1 (F-9), anti-Lamin B2 (C-20), anti-
Tubulin (TU-02) and anti-cytokeratin 16 (sc-53255) were obtained
from Santa Cruz Biotechnology (Dallas, Texas, USA). anti-NRF2
(D1Z9C) was obtained from Cell Signaling Technology (Danvers, MA,
USA), anti-HMOX1 (ab13243) and anti-cytokeratin 17 (ab109725)
were obtained from Abcam (Cambridge, UK). HRP-conjugated sec-
ondary antibodies were obtained from Life Technologies (Carlsbad,
California, USA). The siRNAs used as control or against BACH1, NRF2
and KEAP1 were the SMART pool: ON-Target Plus from Dharmacon
(Lafayette, CO, USA). MG132 was obtained from Santa Cruz
Biotechnology, and Leptomycin B was obtained from Cayman
Chemicals (Ann Arbor, MI, USA). 9Δ-THC was purchase to Sigma
Aldrich (San Louis, MI, USA) and other cannabinoids with a purity
higher than 97% were obtained from Prof. Giovanni Appendino
(University of Eastern Piedmont, Novara, Italy).
2.3. RNA-Seq
Total RNA was isolated from NHEK cells by Qiazol lysis reagent
(Qiagen, Hilden, Germany) and puriﬁed with miRNeasy mini kit
(Qiagen) following manufacturer's instructions. RNA was processed for
high throughput sequencing using the Illumina TruSeq mRNA Sample
Prep v2 kit (RS-122-2001). Transcriptome libraries were constructed by
polyA puriﬁcation. In brief, 1 μg of total RNA from each sample was
used to construct a cDNA library, followed by sequencing on the
Illumina HiSeq 2500 system with single end 50 bp reads and ~30
millions of reads per sample.
2.4. SWATH LC-MS/MS proteomics
Proteins were obtained by lysing NHEK cells in NP-40 buﬀer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and 1% NP-40)
supplemented with protease and phosphatase inhibitors and cleaned to
remove contaminants by protein precipitation with TCA/acetone and
solubilized in 50 μl of 0.2% RapiGest (Waters, Milford, MA, USA) in
50 mM ammonium bicarbonate. Protein extracts were subjected to
trypsin digestion. RePLiCal iRT (PolyQuant GmbH, Bad Abbach,
Germany) peptides were added to the peptide samples in order to ca-
librate retention times in the SWATH runs. Samples (1 μg) were ana-
lysed by LC-MS/MS using a data-independent SWATH acquisition using
a Triple TOF 5600 + mass spectrometer (Sciex) coupled to a nLC
system with a 2 h gradient (5%–30% ACN 0.1% formic acid, 300 nL/
min, column: Thermo PepMap100 25 cm x 75 μm id). For building the
spectral library, shotgun data-dependent acquisition runs (top 65
method) were performed on the same LC-MS equipment and gradient.
2.5. Transcriptomic and proteomic data analysis
RNA-Seq reads were pre-processed with Trimmomatic (v0.36) [27]
and aligned to human genome assembly hg38 using HISAT2 (v2.1.0)
[28]. Then, counts per gene were obtained with featureCounts (v1.6.1)
[29] and the diﬀerential expression analysis was carried out using
DESeq2 (v1.20.0) [30] excluding those genes with less than 15 counts
across all samples. For proteomics, proteins and peptides were identi-
ﬁed from the DDA shotgun runs using ProteinPilot (v5.0) and a con-
catenated target-reverse decoy SwissProt human protein database. A
spectral library was built using the MS/MS ALL with SWATH Acquisi-
tion MicroApp (v2.0) using the peptides that showed up in the database
search with a conﬁdence score above 99%. The library-assisted targeted
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data extraction of the fragment ion chromatogram traces from the
SWATH runs, and the retention time calibration, was performed by
PeakView (v2.1) using the MS/MSALL with SWATH Acquisition Mi-
croApp (v2.0), using a 1% FDR threshold and 50 ppm of tolerance.
MarkerView (v1.2.1, Sciex) was used for signal normalization. Diﬀer-
ential abundance analysis was performed by applying a Welch Two
Sample T-Test to compare normalized SWATH areas between groups.
For the functional analysis, genes with an adjusted P < 0.05 and an
absolute fold change>2 and proteins with an adjusted P < 0.05 and
an absolute fold change>1.5 were selected to perform an over-re-
presentation analysis. For this, the EnrichR tool was employed using
Gene Ontology (Biological Process) terms, Wikipathways and tran-
scription factors from JASPAR [31]. Finally, a gene set enrichment
analysis was carried out for transcriptomic data with the fgsea (v1.9.7)
package, using the same gene sets and pre-ranking the whole gene list
by the log2 transformed fold change. All the P values from the diﬀerent
analyses were adjusted to control the false discovery rate (FDR) using
the Benjamini and Hochberg approach [32]. RNA-seq data have been
deposited in the Gene Expression Omnibus (GEO) databank with the
dataset identiﬁer GSE131565. The mass spectrometry proteomics data
have been deposited to the ProteomeXchange Consortium via the
PRIDE [33] partner repository with the dataset identiﬁer PXD013956.
2.6. Quantitative real time PCR (rt-qPCR)
RNA was extracted using RNeasy kit (Qiagen). 500 ng of RNA per
sample was reverse-transcribed to cDNA using Omniscript RT kit
(Qiagen) supplemented with RNase inhibitor according to the manu-
facturer's instructions. Resulting cDNA was analysed using TaqMan
Universal Master Mix II (Life Technologies, Carlsbad, CA, USA). Gene
expression was determined using an Applied Biosystems 7300 Real-
Time PCR system by the comparative ΔΔCT method. All experiments
were performed at least in triplicates and data were normalized to the
housekeeping gene HPRT1. The primers used are listed in
Supplementary Table S1.
2.7. siRNA cell transfections
On the day prior to transfection, cells were plated to the required
cell density (70–90% conﬂuency). The siRNA and Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA, USA) were individually diluted in
Optimem (Life Technologies) and incubated for 10min at room tem-
perature. Diluted siRNA was added to the diluted Lipofectamine solu-
tion (1:1 ratio) and further incubated for 15min. The complex was
added to the cells and incubated in a humidiﬁed incubator at 37 °C and
5% CO2 for 36 h prior treatment and lysis.
2.8. Cell lysis protocol and western blotting
Cells were washed and harvested in ice-cold phosphate-buﬀered
saline (PBS) and lysed in either SDS buﬀer or RIPA buﬀer [50mM Tris-
HCl pH 7.5, 150mM NaCl, 2 mM EDTA, 1% NP40, 0.5% sodium
deoxycholate, 0.5mM Na3VO4, 50mM NaF, 2 μg/ml leupeptine, 2 μg/
ml aprotinin, 0.05mM pefabloc]. Cells directly lysed in SDS were boiled
for 2min, sonicated and boiled again for another 5min. Cells lysed in
RIPA buﬀer were sonicated and lysates were cleared by centrifugation
for 15min at 4 °C. Protein concentration was established using the BCA
assay (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Supernatant was
mixed with SDS sample buﬀer and boiled for 5min. Equal amounts of
protein were separated by SDS-PAGE, followed by semidry blotting to a
polyvinylidene diﬂuoride membrane (Thermo Fisher Scientiﬁc). After
blocking of the membrane with 5% (w/v) TBST non-fat dry milk, pri-
mary antibodies were added. Appropriate secondary antibodies coupled
to horseradish peroxidase were detected by enhanced chemilumines-
cence using Clarity™ Western ECL Blotting Substrate (Bio-Rad,
Hercules, CA, USA).
2.9. Subcellular fractionation (nuclear/cytoplasmic separation)
Cells were washed and harvested with ice-cold PBS. Pelleted cells
were resuspended in 400 μl of low-salt buﬀer A (10mM Hepes/KOH
pH7.9, 10mM KCL, 0.1 mM EDTA, 0.1 mM EGTA, 1mM β-
Mercaptoethanol). After incubation for 10min on ice, 10 μl of 10% NP-
40 was added and cells were lysed by gently vortexing. The homo-
genate was centrifuged for 10 s at 13,200 rpm in a microfuge. The su-
pernatant representing the cytoplasmic fraction was collected and the
pellet containing the cell nuclei was washed 4 additional times in buﬀer
A, then resuspended in 100 μl high-salt buﬀer B (20mM Hepes/KOH
pH7.9, 400mM NaCL, 1mM EDTA, 1mM EGTA, 1mM β-mercap-
toethanol). The lysates were sonicated and centrifuged at 4 °C for
15min at 13,200 rpm. The supernatant representing the nuclear frac-
tion was collected. Protease and phosphatase inhibitors were freshly
added to both buﬀers.
2.10. Determination of heme
Heme levels were detected using the Hemin Assay Kit (MAK036,
Sigma-Aldrich) according to manufacturer's instructions. Brieﬂy,
2× 106 cells were homogenized in 4 vol of cold hemin assay buﬀer.
Samples were centrifuged at 13000×g for 10min at 4 °C to remove the
cellular debris and diluted with hemin assay buﬀer. After adding the
proper reaction mix and incubate for 10min, absorbance was measure
at 570 nm in a kinetic mode. Data were shown as amount of heme
(fmole) using a hemin standard curve.
2.11. Luciferase assays
HaCaT-ARE-Luc cells were stimulated with either Sulforaphane
(SFN) (5 μM) or with increasing concentrations of cannabinoids for 6 h.
After the treatment the cells were washed twice in PBS and lysed in
25mM Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-
100, and 7% glycerol during 15min at room temperature in a hor-
izontal shaker. After centrifugation, luciferase activity in the super-
natant was measured using a GloMax 96 microplate luminometer
(Promega) following the instructions of the luciferase assay kit
(Promega, Madison, WI, USA). Results are expressed in RLU over con-
trol untreated cells.
2.12. ROS determination
The intracellular accumulation of ROS was detected using 2',7-'di-
hydroﬂuorescein-diacetate (DCFH-DA). HaCaT cells (15×103 cells/
Fig. 1. Multi-omic analysis of the response of keratinocytes to CBD. The transcriptomic and proteomic proﬁling of RNA and protein samples was carried out
using RNA-Seq and LC-MS/MS, respectively. (A, B) Volcano plots showing the magnitude (log2 fold change) and signiﬁcance (-log10 p value) of the changes in the
transcriptomic and proteomic comparisons of CBD treated keratinocytes versus controls (n=3 for RNA-Seq and n= 4 for proteomics). Every point represents a
gene/protein and the colour indicates those surpassing the cut-oﬀ of an adjusted P value < 0.05 and an absolute fold change> 2 (for genes) or > 1.5 (for proteins).
For RNA-Seq, a small value (1e-300) was added to p values in order to avoid logarithms of zero at plotting. (C) Upset plot indicating the overlap between the sets of
up or down regulated genes and proteins as a bar plot over a coincidence histogram. (D) Over-representation analysis results. The dot plot indicates with a point the
signiﬁcant over-representation of a given term, transcription factor or pathway in a group of up or down regulated genes/proteins (Fisher Exact Test adjusted
P < 0.1). While the colour indicates the adjusted P value of the enrichment, the size of the point represents the enrichR combined score.
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well) were cultured in a 96-well plate in DMEM supplemented with
10% FBS until cells reached 80% conﬂuence. For induction of ROS the
cells were treated with increasing concentrations CBD. For inhibition,
the cells were pre-treated with CBD for 30min and treated with 0,4mM
Tert-butyl-hydroperoxide (TBHP). Three hours later the cells were in-
cubated with 10 μM DCFH-DA in the culture medium at 37°C for
30min. Then, the cells were washed with PBS at 37°C and the pro-
duction of intracellular ROS measured by DCF ﬂuorescence was de-
tected using the Incucyte FLR software, the data were analysed by the
total green object integrated intensity (GCUxμm2xWell) of the imaging
system IncuCyte HD (Sartorius, Göttingen, Germany). N-Acetyl cysteine
(NAC) (15mM) was used as a positive control that inhibited TPHP-in-
duced ROS production.
2.13. Animal studies
Six-months old female BALB/cByJRj mice were obtained from
Janvier Labs (Le Genest-Saint-Isle, France). Animals were housed in
groups (control n= 3, CBD 0.1% n=6, and CBD 1% n=6) at
20–22 °C under constant conditions of light (14 h of light; lights on at
7:00 a.m.) and 40–50% relative humidity with free access to standard
food and water. The back of the mice was shaved, and the animals were
treated topically with vehicle (10% DMSO in propylene glycol), CBD
0.1%, 1% or 10% once a day for 5 days. At the end of the experiment,
mice were euthanized, and mouse skin was collected, ﬁxed in 4%
paraformaldehyde and embedded in paraﬃn for subsequent histolo-
gical analysis. All experiments were performed in accordance with
European Union guideline and approved by the Animal Research Ethic
Committee of The University of Córdoba (2014PI/025).
2.14. Histology and immunohistochemistry
Five-μm sections from mouse skin were deparaﬃnised with xylene
and rehydrated with decreasing concentration of ethanol and water.
Then, sections were stained with haematoxylin for 5 min, washed in
running water and diﬀerentiated in acid ethanol for a few seconds.
Once rinsed, sections were stained with eosin for 30 s and dehydrated
with increasing concentration of ethanol. Finally, after a 2-min xylene
bath, samples were mounted and analysed under the microscope. For
IHC, antigen retrieval was performed by microwave heating for 5 min
in citrate buﬀer (10 mM, Ph 6.0) for cytokeratins and HMOX1 anti-
bodies. Neutralization of endogenous peroxidase was performed using
EnVision FLEX-peroxidase blocking reagent (Agilent Dako, Glostrup,
Denmark) for 10 min. Samples were blocked with 3% bovine serum
albumin for 30 min, and the mouse-on-mouse staining protocol (Rodent
Block M, RBM961L, Biocare Medical, Pacheco, CA, EEUU) was used for
cytokeratin 16 mouse antibody. Then, tissue sections were incubated
with primary antibodies overnight at 4 °C. Samples were incubated with
EnVision FLEX + mouse/rabbit linker and EnVision FLEX/HRP
(Agilent Dako), for 30 min at RT each. Finally, detection was performed
using 3,3′-diaminobenzidine (DAB) chromogen and sections were
counterstained with haematoxylin, dehydrated, mounted and analysed
with a Leica DM2000 microscope. Pictures were taken with a Leica
MC190 camera. The quantiﬁcation of IHCs was performed measuring
the stained area in the epidermis from more than 8 ﬁelds per condition
with ImageJ software (Bethesda, MD, USA).
2.15. Statistical analyses
Most experiments were repeated 3–5 times with multiple technical
replicates to be eligible for the indicated statistical analyses. Data were
analysed using Graphpad Prism statistical package. All results are pre-
sented as mean ± SD unless otherwise mentioned. For animal studies,
ﬁve-eight mice per group was the standard sample size as deﬁned by
statistical power analyses (80% power; p < 0.05) carried out using R
packages. The investigators were not blinded to allocation during ex-
periments and outcome assessment. When applicable, the diﬀerences
between groups were determined by either one-way ANOVA or 2-way
ANOVA. A P value of< 0.05 was considered signiﬁcant. *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
3. Results
3.1. Proteomics and transcriptomic analysis in primary keratinocytes
treated with CBD
To obtain a ﬁrst insight into the changes produced by CBD in epi-
dermal cells, primary human keratinocytes were incubated with either
solvent or CBD (10 μM) for 24 h and transcriptomic and proteomic
changes were analysed through RNA-Seq and SWATH LC-MS/MS, re-
spectively. From 17571 genes quantiﬁed the treatment with CBD al-
tered the expression (adjusted P < 0.05 and absolute fold change >
2) of 4860 genes, of which 2374 were downregulated and 2486 up-
regulated (Fig. 1A). At the proteome level, 724 out of 2204 quantiﬁed
proteins surpassed the cut-oﬀ (adjusted P < 0.05 and absolute fold
change > 1.5). From them, 520 decreased and 204 increased their
abundance (Fig. 1B). Additionally, 147 features were found to be sig-
niﬁcantly altered in the same direction at both levels when comparing
the overlap between the mRNA and protein sets (Fig. 1C). Finally, to
explore the functional impact of the observed changes, we performed
an over-representation analysis of the diﬀerent sets of up and down
regulated genes and proteins using enrichR. We found several pathways
enriched (adjusted P < 0.1) in the group of up-regulated features re-
lated with the skin biology as “epidermal cell diﬀerentiation”, “kera-
tinocyte diﬀerentiation”, “skin development” and also transcription
factors such as the NRF2 (“NFE2L2” and “NRF2 pathway”). On the
other hand, we found terms and pathways that were enriched in the
group of down-regulated genes and proteins as “extracellular matrix
organization”, “DNA metabolic process” and “Cell Cycle” (Fig. 1D). This
functional portrait of the transcriptomic and proteomic changes sug-
gested that CBD may promote keratinocyte proliferation and diﬀer-
entiation, and upregulated genes and proteins implicated in skin de-
velopment. However, the result that strongly caught our attention was
the activation of the transcriptional activity of NRF2, given the im-
portance of this antioxidant transcription factor in keratinocyte biology
[34].
3.2. Validation of the NRF2 pathway as a target of CBD in keratinocytes
In order to validate the data obtained from the RNA-Seq and mass
spectrometry analysis, we selected candidates that were highly induced
by CBD at both protein and mRNA levels (i.e SQSTM1, also known as
p62, and HMOX1) (Fig. 2A–B), and we tested by qRT-PCR the eﬀect of
Fig. 2. Validation of the NRF2 pathway as a target of CBD in keratinocytes. (A) Gene set enrichment analysis plot for the NRF2 signalling pathway tran-
scriptomic changes. Black lines indicate the position of NRF2 genes in the pre-ranked gene list and the green line indicates the running enrichment score. (B)
Magnitude of the changes for signiﬁcantly up-regulated genes and proteins selected using the previously mentioned cut-oﬀs in the CBD versus control comparison. C)
Primary human keratinocytes were incubated with either DMSO or CBD (10 μM) for 24 h. The mRNA levels for HMOX1 (upper panel) and SQSTM1 (p62) (lower panel)
were quantiﬁed using real-time PCR. The data were normalized using HPRT1 as an internal control. Data represent means ± SD (n = 3) and are expressed relative
to the DMSO sample. ***P ≤ 0.001. D) HaCaT cells were incubated with either DMSO or increasing concentration of CBD for 16 h. The mRNA levels for HMOX1
(upper panel) and SQSTM1 (p62) (lower panel) were quantiﬁed using real-time PCR as previously indicated (n= 3) *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001. E) HaCaT-
ARE-Luc cells were treated with either SFN or CBD at the indicated concentrations for 6 h. Luciferase activity was measured in the cell lysates and expressed as RLU (x
104). Data represent means ± SD (n = 4) and are expressed relative to untreated cells. **P ≤ 0.01, ***P ≤ 0.001.
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CBD on their expression in primary human keratinocytes (Fig. 2C) and
in the immortalised human keratinocyte cell line HaCaT (Fig. 2D). Our
results showed that in fact, CBD treatment induced the expression of the
selected NRF2 target genes in both primary and immortalised human
keratinocytes. Furthermore, using a HaCaT NRF2 reporter (ARE-luc)
cell line we tested if CBD was also able to activate a synthetic reporter
gene containing the ARE sequence from the NQO1 promoter fused to
luciferase. Our results show that when compared with the potent NRF2
activator sulforaphane (SFN), CBD is a weak inducer of ARE-Luc
(Fig. 2E).
3.3. CBD activates a subset of NRF2 target genes
Compounds or drugs that activate the NRF2 pathway could act ei-
ther directly by stabilising NRF2, or indirectly by inducing ROS which
will consequently activate NRF2. Examples of the former are the natural
compound sulforaphane [35] and the synthetic compound TBE31 [36].
As CBD, albeit weak, appeared to be an activator of NRF2, we wondered
whether it was a direct activator, or if, as it has been suggested in the
literature, CBD activates NRF2 indirectly by inducing ROS [37,38]. Our
results showed that CBD, at the concentrations previously used, not
only did not induce ROS, but it was able to reduce ROS levels induced
by tBHP (tert-Butyl hydroperoxide) in a concentration-dependent
manner (Fig. 3A). Secondly, as CBD was only weakly inducing the ex-
pression of an ARE-luc construct, we further tested whether CBD was a
good NRF2 activator. To do so, we compared the eﬀect of CBD and SFN
on the expression of a panel of NRF2 target genes (Fig. 3B). Interest-
ingly, CBD was equally or more potent than SFN at inducing the ex-
pression of a subset of NRF2 target genes (e.g. HMOX1, GCLC and p62),
but dramatically less potent inducing the expression of other NRF2
target genes (i.e the aldo-ketoreductases AKR1B10 and AKR1C1).
HMOX1 was the gene in which the eﬀect of CBD was clearer and in
which CBD was signiﬁcantly more potent than SFN. To further char-
acterise the diﬀerences between CBD and SFN we studied the kinetics of
HMOX1 induction in response to either CBD or SFN (Fig. 3C). Our data
showed that in response to SFN, HMOX1 induction peaked at 8 h after
treatment (14-fold mean induction), returning to basal levels at 16 h. In
contrast, CBD treatment maintained a high HMOX1 expression at 16 h
(53-fold mean induction) suggesting that CBD has a stronger or a more
persistent eﬀect on HMOX1 than that of SFN. Notably, other cannabi-
noids such as 9Δ−THC, CBC or CBG were less potent in inducing
HMOX1, and their acidic forms were completely inactive (Fig. S1A).
SFN, as most electrophilic compounds, acts via KEAP1, but as CBD is
not electrophilic, we hypothesized that CBD might act in a KEAP1-in-
dependent manner. To test this hypothesis, we tested the eﬀect of CBD
on HMOX1 expression in control cells or in cells were KEAP1 had been
depleted. Our results showed that CBD was still able to induce the ex-
pression of HMOX1 in KEAP1 knocked-down cells (Fig. 3D), demon-
strating that the eﬀect of CBD is independent of KEAP1. Interestingly,
although KEAP1 knockdown greatly induced the expression of AKR1C1
(Fig. S1B), HMOX1 basal levels were not signiﬁcantly changed by
KEAP1 knockdown, revealing that in this setting, activation of NRF2 by
itself is not enough to induce HMOX1 expression.
To further compare CBD and SFN, we directly assessed their eﬀect
on NRF2 protein levels. While SFN treatment strongly stabilised NRF2
protein levels, the eﬀect of CBD was very mild in comparison (Fig. 3E).
All together, these results suggest that a) the mechanism of action of
both compounds is diﬀerent; and b) the strong eﬀect of CBD on HMOX1
expression does not correlate with its weak eﬀect on NRF2 stability, and
therefore NRF2 activation is not likely the main mechanism responsible
for CBD-mediated HMOX1 activation.
3.4. CBD activates HMOX1 in a BACH1-dependent manner
Based on our results, CBD only weakly stabilises NRF2, and its po-
sitive eﬀect on NRF2 target genes is restricted to a subset of genes.
Previous studies in keratinocytes have shown that while KEAP1
knockdown led to a weak induction of HMOX1 (2-5-fold induction),
BACH1 knockdown strongly induced HMOX1 (135-fold induction)
without aﬀecting other NRF2 target genes (i.e aldo-ketoreductases)
[14]. Therefore, BACH1 appeared as a potential molecular target for
CBD that could explain the observed selective transcriptional eﬀect. To
test this hypothesis, we compared the induction of HMOX1 in response
to CBD in HaCaT cells transfected with either siControl or siBACH1. In
agreement with previous reports, BACH1 knockdown by itself strongly
induced HMOX1 levels (mean 51-fold) (Fig. 4A, upper left panel). Im-
portantly, CBD induced the expression of HMOX1 in control cells (mean
58-fold) but its eﬀect was greatly reduced in BACH1 knocked-down
cells (mean 10-fold) (Fig. 4A, upper right panel), showing the relevance
of BACH1 for the eﬀect of CBD on HMOX1. Moreover, BACH1 depletion
also abolished the induction of HMOX1 mediated by the BACH1 in-
hibitor hemin, but not the one mediated by SFN (Fig. S2A), further
demonstrating the diﬀerent mechanism of action used by CDB and
hemin in comparison with SFN.
Most described regulatory mechanisms for BACH1 are at post-
translational level, aﬀecting either its localisation and/or stability. For
instance, the main negative regulator of BACH1, heme, inactivates
BACH1 leading to its nuclear exclusion and cytosolic degradation
[13,39,40]. To test if CBD had an eﬀect on the levels of BACH1, we
exposed HaCaT cells to increasing concentrations of CBD and measured
BACH1 protein levels. Our data showed that CBD dramatically reduced
both, BACH1 total (Fig. 4B) and BACH1 nuclear levels (Fig. 4C) in a
dose dependent manner, and that this eﬀect is obvious as soon as 2 h
after CBD treatment (Fig. 4D). Compared with SFN, CBD is a weak in-
ducer of NRF2, but a potent BACH1 inhibitor (Fig. 3E and Fig. 4B). To
test whether CBD was inducing BACH1 proteasomal degradation in
either the nucleus or the cytoplasm, we pre-treated the cells with or
without the proteasome inhibitor MG132 and analysed the eﬀect of
CBD on BACH1 nuclear and cytosolic levels (Fig. 4E). Interestingly,
CBD treatment led to reduction of nuclear BACH1, which was not re-
covered by MG132, suggesting that BACH1 is not degraded in the nu-
cleus. On the other hand, CBD treatment in presence of MG132 led to
accumulation of cytosolic BACH1. Based on these results we hypothe-
sized that CBD treatment might induce BACH1 nuclear export and its
cytosolic degradation. To further test that hypothesis, we treated cells
with or without the nuclear export inhibitor leptomycin B in combi-
nation with CBD (Fig. 4F). Our results showed that leptomycin B
completely abolished the eﬀect of CBD on BACH1 levels. Altogether,
our data demonstrate that CBD leads to BACH1 degradation via a me-
chanism that involves BACH1 nuclear export and cytosolic degradation.
The mechanism by which CBD regulates BACH1 resembles the one
shown for the BACH1 inhibitor hemin [13,39,40]. These similarities
Fig. 3. CBD activates a subset of NRF2 target genes. A) ROS detection in HaCaT labelled with DCFH-DA, HaCaT cells was treated as indicated and the detection
and quantiﬁcation of ROS (DCF ﬂuorescence) measured by ﬂuorescence microscopy (left panel). Data represent means ± SD (n = 5) and are expressed relative to
control cells. **P ≤ 0.01, ***P ≤ 0.001. Representative pictures are shown in the right panel. B) HaCaT cells were incubated with either DMSO, SFN (5 μM), or
increasing concentration of CBD for 16 h. The mRNA levels for the indicated genes were quantiﬁed using real-time PCR. The data were normalized using HPRT1 as an
internal control. Data represent means ± SD (n = 3) and are expressed relative to the DMSO sample. *P≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P≤ 0.0001. C)
HaCaT cells were incubated with either DMSO, SFN (5 μM), or increasing concentration of CBD for 4, 8 and 16 h. The mRNA levels for HMOX1 were quantiﬁed using
real-time PCR as previously indicated (n=3). D) HaCaT cells were transfected with either siControl or siKEAP1. 36 h later cells were incubated with either DMSO,
SFN (5 μM), or CBD (10 μM) for another 16 h. The mRNA levels for HMOX1 were quantiﬁed as previously indicated (n=3). E) HaCaT cells were incubated with
either DMSO (−), CBD or SFN as indicated. Three hours later, cells we lysed, and levels of NRF2 and Tubulin were analysed by Western blot.
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prompted us to study if CBD could be inhibiting BACH1 by modulating
the levels of intracellular heme. Our results showed that CBD did not
increased the levels of heme (Fig. S2B), neither was the eﬀect of CBD on
either BACH1 protein levels or HMOX1 mRNA levels impaired by in-
hibitors of the heme biosynthesis (Figs. S2C and S2D), suggesting that
the eﬀect of CBD is independent of heme.
3.5. CBD induces HMOX1 in a NRF2-independent manner
In the current model, BACH1 depletion is the ﬁrst step before NRF2
could induce HMOX1. Therefore, we hypothesized that as the eﬀect of
CBD on HMOX1 involved BACH1 inhibition, it would be impaired by
NRF2 depletion. Surprisingly, NRF2 knockdown did not aﬀect CBD-
mediated HMOX1 induction (Fig. 5A) although, it impaired the SFN-
mediated AKR1C1 induction (Fig. S3A). To conﬁrm our results using a
complementary approach, we produced CRISPR-mediated NRF2-KO
HaCaT cells. We veriﬁed that these cells had no detectable NRF2 pro-
tein levels (Fig. S3B), and signiﬁcantly lower mRNA levels of NQO1 and
AKR1B10, two of the best markers for NRF2 activity (Fig. S3C). Using
these cells, we found that in agreement with our siRNA approach, both
CBD and hemin were still able to strongly induce HMOX1 in the absence
of NRF2 (Fig. 5B), while the eﬀect of SFN was completely abolished
(Fig. S3D), suggesting that NRF2 is not necessary for HMOX1 induction
mediated by BACH1. However, as both compounds, CBD and hemin,
are likely to target other proteins in addition to BACH1, their eﬀect on
HMOX1 might not be solely dependent on BACH1. To test this possi-
bility, we directly assessed the eﬀect of knocking down BACH1 on
HMOX1 levels in NRF2-KO cells, with or without CBD or hemin treat-
ment. BACH1 knockdown by itself led to a strong induction of HMOX1
in NRF2-KO HaCaT cells (mean 50-fold) (Fig. 5C, upper left panel), si-
milar to the induction observed in WT HaCaT cells (Fig. 4A), showing
that NRF2 is not necessary for the HMOX1 induction upon BACH1 de-
pletion. Additionally, both CBD and hemin strongly induced HMOX1 in
NRF2-KO HaCaT cells, and BACH1 depletion almost completely im-
paired the induction of HMOX1 mediated by both compounds (Fig. 5C,
upper right panel). These results demonstrate that: a) the eﬀect of CBD
and hemin on HMOX1 expression is BACH1-dependent and NRF2-in-
dependent; and b) in HaCaT cells, NRF2 is not necessary for BACH1-
mediated HMOX1 induction.
3.6. Eﬀect of topical CBD in skin in vivo
Next, we treated mice with concentrations of topically-applied CBD
that mimic the range of concentrations found in commercially available
CBD-based products (0.1–1%) and studied the eﬀect of CBD on epi-
dermal morphology. As we are interested in the eﬀect of CBD on the
skin of adults (which is the age group for which CBD-based creams is
marketed), we used 6 months old mice, a model that resembles adult
skin. We observed that treatment with CBD induced keratinocyte pro-
liferation (measured by epidermal thickness) (Fig. 6A) and increased
the levels of HMOX1 (Fig. 6B). Moreover, CBD also increased the levels
of cytokeratins 16 and 17 (Fig. 7A), which are associated with kerati-
nocyte hyperproliferation [41] and wound repair [42]. Although both
HMOX1 and KRT16 and KRT17 are also considered markers of stress
and inﬂammation, CBD did not induce the expression of typical pro-
inﬂammatory cytokines (i.e IL1β, IL6 and TNFα) (Fig. S4) suggesting
that the eﬀect of CBD on HMOX1 is not due to an inﬂammatory re-
sponse.
4. Discussion
The potential use of CBD for treatment of skin disorders and cos-
metic indications is gaining momentum, although the mechanism of
action of CBD on diﬀerent skin cell types is not understood [43,44].
Using a system biology approach combining transcriptomic and pro-
teomic data we have identiﬁed for the ﬁrst time the major pathways
that are regulated by CBD on human primary keratinocytes cultivated
under non-diﬀerentiating conditions, which could explain some of the
potential beneﬁcial eﬀects of CBD in the skin. Importantly, although a
potential link between CBD and the NRF2 pathway has been suggested
in other cells types, no molecular mechanism has been identiﬁed so far.
In that sense, our work reveals for the ﬁrst time the link connecting CBD
with the NRF2 pathway. However, although our study does not identify
the speciﬁc molecular mechanism by which CBD induces BACH1 cy-
tosolic degradation, our results suggest that it is independent on the
levels of heme, and thus a diﬀerent mechanism than the one used by the
BACH1 inhibitor Hemin. A recent report showed that Fbxo22 is the E3
ligase responsible for the degradation of BACH1 [45]. Due to the rapid
eﬀect of CBD on BACH1 levels, we hypothesise that CBD might be di-
rectly aﬀecting the same or a diﬀerent E3 ligase controlling BACH1
turnover.
It is interesting that although one of the signatures identiﬁed in our
system biology analysis was the NRF2 pathway, which suggested that
CBD could be an NRF2 activator, our biochemical analysis demon-
strated that CBD is a weak NRF2 activator but a potent BACH1 in-
hibitor, and thus BACH1 is the main target of CBD in keratinocytes. As
the transcriptional signature of BACH1 overlaps with that of NRF2, it is
not unexpected that a BACH1 inhibitor presents a signature partially
similar to an NRF2 activator. Nevertheless, our analysis shows that CBD
is also a weak inducer of NRF2, which could be an indirect eﬀect of its
negative eﬀect on BACH1. A potential explanation could be that as
BACH1 repress p62 expression, and CBD inhibits BACH1 increasing p62
levels, CBD might stabilise NRF2 indirectly by inducing the expression
of the KEAP1 competitor p62 [46].
The best characterised BACH1 target is HMOX1, which is the mRNA
and the protein that was most regulated by CBD in our analyses.
Fig. 4. CBD activates HMOX1 in a BACH1-dependent manner. A) HaCaT cells were transfected with either siControl or siBACH1. 36 h later, cells were incubated
with either DMSO or CBD (10 μM) for another 16 h. To measure the eﬀect of BACH1 depletion on HMOX1 expression, the mRNA levels for HMOX1 in siControl and
siBACH1 DMSO treated cells were quantiﬁed using real-time PCR as previously described (upper left panel). To compare the HMOX1 induction upon CBD treatment in
each cell line, the levels of HMOX1 in either siControl CBD or siBACH1 CBD samples were compared against the levels of HMOX1 in siControl DMSO or siBACH1
DMSO samples respectively (HMOX1 levels in DMSO samples were set in both cases as 1) (upper right panel). The CBD-mediated HMOX1 induction in both cell lines
was quantiﬁed by real-time PCR using HPRT1 as an internal control. Data represent means ± SD (n=3). To control for the eﬃciency of the knockdown, the mRNA
levels (lower left panel) and protein levels (lower right panel) of BACH1 were analysed by real-time PCR and western blot respectively. *P ≤ 0.05, **P ≤ 0.01 . B)
HaCaT cells were incubated with either DMSO (−), CBD or SFN as indicated. Three hours later, cells we lysed, and levels of BACH1 and Tubulin were analysed by
Western blot. (These blots and the blots from Fig. 3E are from the same experiment, and thus share the same tubulin. For clarity's sake we decided to show them in
two diﬀerent subﬁgures). C) HaCaT cells were incubated with either DMSO (−) or increasing concentrations of CBD. Three hours later, cells were collected, nuclear
and cytosolic fractions were isolated and the nuclear fraction was analysed for the levels of BACH1 and NRF2. D) HaCaT cells were incubated with either DMSO or
CBD (10 μM) for diﬀerent periods of time as indicated. Cells were lysed and protein levels of BACH1 were analysed. E) HaCaT cells were incubated with either DMSO
(−) or MG132 (10 μM). Two hours later, CBD was added. Three hours later, cells were collected, nuclear and cytosolic fractions were isolated and analysed for the
levels of BACH1. Upper panel is a representative western blot; lower panel shows the quantiﬁcation of BACH1 protein levels in the nuclear and cytosolic fraction
normalized against their respective loading controls. Data represent means ± SD (n= 3) and are expressed relative to the DMSO samples. F) HaCaT cells were
incubated with either DMSO (−) or Leptomycin B (LMB) (5 nM). Two hours later, CBD (10 μM) was added for another 3 h. After that, cells were lysed and protein
levels of BACH1 were analysed.
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Unexpectedly, we identiﬁed that the HMOX1 induction mediated by
CBD was NRF2 independent. In the current general model of HMOX1
activation, BACH1 and NRF2 work together controlling its expression.
However, pioneer work in mice showed that although that is true for
some tissues (i.e. lung, heart and liver), in thymus the induction of
HMOX1 in response to BACH1 depletion was independent of NRF2
[47]. Our results demonstrate that in HaCaT cells, NRF2 is not neces-
sary for the induction of HMOX1 upon BACH1 depletion/inhibition,
supporting a novel regulatory mechanism involving BACH1 and an
unidentiﬁed positive regulator. This agrees with the original
(caption on next page)
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publication, showing that the role of NRF2 controlling HMOX1 ex-
pression might be redundant with other activators in a tissue/cell line
speciﬁc manner. Although NRF2 is the main positive regulator, HMOX1
expression can also be regulated by other members of the CNC (NRF1
and NRF3) and MAF family (large and small MAFs), HSF1, c-jun, AP1
and NF-κB [48], and thus either of these factors could be responsible for
the induction of HMOX1 in response to BACH1 depletion/inhibition. As
CBD induces the expression of a MAFB expression signature (Fig. 1D)
and also of small MAFF and MAFG (Fig. 2B), these members of the MAF
family could potentially be involved in the positive regulation of
HMOX1 in the absence of BACH1. Further work is necessary to address
which factors can compensate for the lack of NRF2 in the diﬀerent
tissues, and in HaCaT and primary keratinocytes in particular.
In skin, HMOX1 is an important cytoprotective enzyme with anti-
oxidant, anti-inﬂammatory and anti-apoptotic properties. Due to such
protective roles, treatments that regulate HMOX1 expression would be
useful for the treatment of inﬂammatory- or oxidative stress-associated
skin conditions. In these scenarios, BACH1 inhibitors might be very
useful, due to their potent activity as HMOX1 inducers. Our validation
of CBD as an BACH1 inhibitor suggests that CBD treatment would a)
protect the skin against external insults: e.g. against UVA-irradiation-
induced damage; and b) be greatly beneﬁcial in a variety of skin
Fig. 5. CBD activates HMOX1 in a NRF2-independent manner. A) HaCaT cells were transfected with either siControl or siNRF2. 36 h later cells were incubated
with either DMSO, CBD (10 μM) or SFN (5 μM) for another 16 h. The mRNA levels for HMOX1 (left panel) and NRF2 (right panel) were quantiﬁed using real-time PCR.
The data were normalized using HPRT1 as an internal control. Data represent means ± SD (n = 3) and are expressed relative to the siControl DMSO sample.
**P ≤ 0.01, ***P ≤ 0.001. B) Control (WT) and NRF2-KO HaCaT cells were incubated with either DMSO, CBD or Hemin (10 μM). 16 h later, the mRNA levels for
HMOX1 were quantiﬁed using real-time PCR as previously described (n= 3). C) Control (WT) and NRF2-KO HaCaT cells were transfected with either siControl or
siBACH1. 36 h later cells were incubated with DMSO, CBD (10 μM) or hemin (10 μM) for another 16 h. To measure the eﬀect of BACH1 depletion on HMOX1
expression, the mRNA levels for HMOX1 in siControl and siBACH1 DMSO-treated cells were quantiﬁed using real-time PCR as previously described (upper left panel).
To compare the HMOX1 induction upon treatment with CBD or hemin in each cell line, the levels of HMOX1 in either siControl CBD/hemin or siBACH1 CBD/hemin
were compared against the levels of HMOX1 in either siControl DMSO or siBACH1 DMSO respectively (HMOX1 levels in DMSO samples were set in both cases as 1)
(upper right panel). The HMOX1 induction in response to either CBD or hemin was quantiﬁed by real-time PCR using HPRT1 as an internal control. Data represent
means ± SD (n= 3). To control for the eﬃciency of the knockdown, the mRNA levels (lower left panel) and protein levels (lower right panel) of BACH1 were analysed
by real-time PCR and western blot respectively. *P ≤ 0.05, **P ≤ 0.01.
Fig. 6. CBD treatment increases the keratinocyte layer in the epidermis and the expression of HMOX1. (A) Haematoxylin-eosin staining of 5 μm paraﬃn-
embedded sections were analysed by bright ﬁeld microscopy. (B) Representative images of HMOX1 immunohistochemistry from mouse skin after 5 days of treatment
with vehicle, CBD 0.1% or 1% (C) Quantiﬁcation of HO-1 stained area in mouse epidermis. *P < 0.05, ***P < 0.001 compared with control. Scale bars: 200 (left)
and 100 μm (right). n = 15 for vehicle treated samples and n = 12 for CBD treated samples.
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conditions, e.g. eczema or atopic dermatitis.
Previous studies have shown that CBD inhibited diﬀerentiation in
HaCaT cells [49], and exerted anti-proliferative actions on transformed
human keratinocytes [50]. Our system analysis in vitro showed an anti-
proliferative and pro-diﬀerentiation proﬁle for CBD, however, our in
vivo data showed that CBD induced keratinocyte proliferation measured
by an increment in both skin thickness and in the levels of the pro-
liferative keratins K16 and K17. HMOX1 has been suggested to induce
keratinocyte proliferation [51], which could explain our results in vivo,
although we cannot rule out the participation of additional proliferative
factors regulated by CBD.
Anectodical evidence suggested that CBD could be indicated for the
treatment of psoriatic plaques. However, psoriasis is characterized by
chronic inﬂammation and keratinocyte hyperproliferation (i.e with
high levels of keratin 16 and 17); therefore, and although CBD has anti-
inﬂammatory eﬀects, we consider that the use of CBD in psoriasis
should be taken with caution due to its pro-proliferative eﬀects in vivo.
Further experiments are required to determine the eﬀect of CBD
treatment in psoriatic lesions in vivo.
The NRF2 activator SFN has been shown to be beneﬁcial for keratin
disorders such as Epidermolysis Bullosa Simplex (EBS). In this context,
topical treatment with SFN rescued skin blistering in an EBS mouse
model, correlating with the reprogramming of keratin synthesis in
epidermis and induction of keratin 16 and 17 [52]. Curiously however,
whereas the SFN-mediated induction of keratin 16 partly depends on
NRF2, the induction of keratin 17 is NRF2-independent [53]. Since
topical and oral CBD have been used by EBS patients with promising
results [22,54] our results provide a mechanistic explanation and sup-
port CBD as a promising option for the prevention of the pathological
skin fragility occurring in EBS and for improving wound closure.
Regarding the safety used of BACH1 inhibitors, long-term BACH1
deﬁciency and associated sustained HMOX1 upregulation in Bach1−/−
mice did not show any detrimental eﬀect under normal conditions [55],
which suggest that acute BACH1 inhibition would not have any sys-
temic deteriorative eﬀect under such conditions.
In summary our study demonstrates for the ﬁrst time a biochemical
target for CBD and provides a scientiﬁc rationale for its use as a
treatment for some skin conditions. Furthermore, recent reports have
highlighted the potential value of BACH1 as a therapeutic target in
cancer [45,56,57], and thus our study also opens the door for new lines
of investigation focused on the potential value of CBD as a cancer
therapeutic drug.
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